← Back to all protocols
17

Peripheral Vasopressor Infusion (Adult Critical Care)Critical Care

Symptoms

  • Indication: shock or hypotension needing vasopressor support when central venous access is not yet available — used as a bridging measure until a central line is placed, or short-term in specific situations
  • Typical situations: stabilising a critically unwell patient awaiting transfer to critical care; short-term post-operative use; patient preference; central access difficult or high-risk
  • Rationale: central line insertion carries its own risks (pneumothorax, arterial injury, arrhythmia, infection). In a systematic review of >1300 patients, peripheral vasopressor extravasation was uncommon (~3.4%) with no tissue necrosis or limb ischaemia reported; other studies show 2–5.5% with only conservative management needed
  • Duration: little data — likely safe for days, but risk rises with time. Maximum rate/duration and review interval should follow local policy and the responsible senior clinician's judgement

Investigations

  • Cannula: at least 20G, sited in the arm proximal to the wrist; avoid flexion sites in awake patients and sites needing more than one venepuncture; confirm blood return and easy flush with 5–10 mL 0.9% saline; ultrasound guidance if needed
  • Site a second peripheral cannula as a contingency; a midline catheter is an alternative if trained staff are available (can stay up to 28 days)
  • Use an infusion pump; invasive BP monitoring recommended — if not used, ensure regular non-invasive BP checks
  • Assess and document the cannula site regularly with a scoring system, looking for swelling, blanching, pain, coolness or discolouration
  • Use standard concentrations (below) — these differ from central-line concentrations and are not interchangeable
  • Only staff trained and competent in vasopressor use should administer; a senior decision-maker should set duration and review interval

Treatment

  • General: dilute in 0.9% sodium chloride or 5% glucose; give by infusion pump; titrate to blood pressure/clinical effect; convert to central access as soon as available. After stopping, flush the cannula with 0.9% saline at the same rate as the infusion to avoid haemodynamic swings. Avoid Y-site co-administration of adrenaline or noradrenaline with other drugs (risk of inadvertent bolus)
  • Noradrenaline: 1 mg/mL concentrate. Standard peripheral concentration 16 micrograms/mL (4 mg noradrenaline = 4 mL + 246 mL 0.9% saline). Start 210 micrograms/hour (13 mL/h) — equals 0.05 micrograms/kg/min in a 70 kg adult — and titrate. Effect wears off 1–2 min after stopping. Usual first-line vasopressor in septic shock (literature)
  • Adrenaline: 1 mg/mL (1:1000). Standard peripheral concentration 16 micrograms/mL (4 mg adrenaline = 4 mL + 246 mL 0.9% saline). Start 210 micrograms/hour (13 mL/h) (0.05 micrograms/kg/min for 70 kg) and titrate. Effect ceases 2–3 min after stopping
  • Metaraminol: 10 mg/mL. Standard peripheral concentration 0.5 mg/mL (20 mg = 2 mL + 38 mL 0.9% saline). Give 0.5–10 mg/hour (1–20 mL/h). Onset 1–2 min; a single dose lasts 20 min to 1 h, so effects taper off after stopping. Caution with digoxin (ectopic arrhythmias). Recommendation based on product information and consensus, not trial data
  • Phenylephrine: 10 mg/mL. Standard peripheral concentration 100 micrograms/mL (50 mg = 5 mL + 495 mL 0.9% saline). Give up to 10.8 mg/hour (108 mL/h) initially, reducing to 1.8–3.6 mg/hour (18–36 mL/h) according to response. Acts for up to 20 min. Contraindicated with monoamine oxidase inhibitors
  • Complication — extravasation (swelling, blanching, pain, cool or discoloured skin): 1) stop the infusion immediately and disconnect the line from the cannula; 2) try to aspirate 3–5 mL through the cannula; 3) remove the cannula and dress the site; 4) mark the affected area to monitor for progression; 5) elevate the limb; 6) consider topical GTN (nitroglycerin) paste to promote local blood flow; 7) give analgesia if needed; 8) seek surgical or tissue-viability advice if concerned; 9) document and report through the incident reporting system
  • Severe ischaemic skin changes after adrenaline/noradrenaline extravasation (literature, not in source): consider Phentolamine 5–10 mg in 10 mL 0.9% saline infiltrated into the affected area, ideally within 12h — seek senior/pharmacy advice
  • Other complications: cannula failure or loss of access → second cannula in place, move to central line; abrupt pressure swings from stopping the infusion or Y-site bolus → flush at the infusion rate and avoid co-infusion; phlebitis → regular site checks and re-site; arrhythmias (adrenaline; metaraminol with digoxin) → reduce dose/monitor ECG; hypertensive reaction with phenylephrine in MAOI-treated patients → avoid
← Back to all protocols